First-line gemcitabine plus nab-paclitaxel for elderly patients with metastatic pancreatic cancer: Crossing the frontier of age?

Gemcitabine plus nab-paclitaxel (Gem-Nab) represents a standard first-line treatment for metastatic pancreatic cancer (mPC), but few data are available for elderly patients. We aimed to add evidence about safety and efficacy of Gem-Nab in this population.

Source: European Journal of Cancer - July 31, 2020 Category: Cancer & Oncology Authors: Caterina Vivaldi, Francesca Salani, Giulia Rovesti, Irene Pecora, Silvia Catanese, Andrea Casadei-Gardini, Valentina Massa, Laura Bernardini, Laura Riggi, Kalliopi Andrikou, Giovanni I. Rapposelli, Vincenzo Formica, Monica Lencioni, Alfredo Falcone, Enric Tags: Original Research Source Type: research